Document › Details
Qiagen N.V.. (6/26/15). "Press Release: Qiagen and Biotype Diagnostics Form Partnership. New »Biotype Innovation« to Develop Workflows for Personalized Health-care and other Applications Based on Qiagen’s ModaPlex Platform". Hilden & Hellerau.
|Organisation 2||Biotype Innovation GmbH|
|Group||ZÖRGIEBEL Group (family of Wilhelm Zörgiebel)|
|Product||companion diagnostic test|
|Product 2||ModaPlex platform|
|Index term||Qiagen–Zörgiebel Group: molecular diagnostics, 201506– collab founding joint venture Biotye Innovation GmbH to develop MDx companion diagnostics|
|Person||Schatz, Peer M. (Qiagen 200511 CEO)|
|Person 2||Zörgiebel, Wilhelm (Biotype Diagnostic 201107 Managing Director + Owner before Priontype 200602 Managing Director)|
QIAGEN and Biotype Diagnostics GmbH today announced that they have entered into a partnership to establish Biotype Innovation GmbH ("Biotype Innovation").
The new company will develop and commercialize molecular diagnostic workflows initially for personalized healthcare applications based on QIAGEN’s proprietary ModaPlex platform, which enables customers to detect, characterize and measure up to 100 parameters simultaneously in a cost-effective and rapid manner.
The diagnostic assays developed by the Biotype Innovation are expected to add to the assay menu of the ModaPlex platform especially in the market for companion diagnostics, which are used to guide drug treatments.
“We are very pleased to join forces with Biotype. This partnership enables us to expand the menu of our unique ModaPlex platform, offer assay development services for pharma companies and thereby expand our leadership in companion diagnostics,” said Peer Schatz, CEO of QIAGEN. “As a long-standing partner with an unparalleled expertise in molecular analysis, Biotype is the natural partner for us.”
QIAGEN will contribute technology and access to its global commercialization engine to the joint venture, while Biotype Diagnostics GmbH will contribute know-how, assay development resources, and its scientific network. QIAGEN will have worldwide distribution rights for the assays, while Biotype Diagnostics will have co-distribution rights for Germany, Austria and Switzerland.
Financial details have not been disclosed.
The partnership, structured as a joint venture, will have its head office based in Hellerau, Dresden, in newly refurbished facilities on the Campus of the Biotype Diagnostics GmbH. “The proximity will allow both companies to leverage synergies and share facilities where necessary”, says Dr. Wilhelm Zörgiebel, CEO of Biotype Diagnostics.
Biotype Innovation GmbH is expected to be fully operational by the 3rd quarter of 2015.
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of March 31, 2015, QIAGEN employed approximately 4,300 people in over 35 locations worldwide. Further information can be found at www.qiagen.com.
About Biotype Diagnostic GmbH
Biotype Diagnostic is a Dresden biotechnology enterprise with more than a decade of experience in the development, production, verification and marketing of testing systems in the field of DNA analytics. The molecular genetic solutions offered by Biotype Diagnostic set new standards in multi-parameter diagnostics and help to clarify medical questions at a genetic level. With a staff of 30, Biotype Diagnostic employs 18 in research and development.
Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation its expected operating results, new product developments, new product launches, regulatory submissions, and financing plans are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products in applied testing, personalized healthcare, clinical research, proteomics, women's health/HPV testing and nucleic acid-based molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products, the consummation of acquisitions, and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).
Record changed: 2016-06-07
More documents for Qiagen (Group)
-  Qiagen N.V.. (2/1/17). "Press Release: Qiagen Reports Results for Fourth Quarter and Full-year 2016". Paris....
-  Qiagen N.V.. (1/26/17). "Press Release: Qiagen’s QuantiFERON-TB Test Wins Tender for Testing of Republic of Korea Armed Forces Recruits". Hilden & Seoul....
-  Qiagen N.V.. (1/19/17). "Press Release: Qiagen Announces Intention to Adjust the Conversion Ratio under Its 0.375% Senior Unsecured Convertible Notes due 2019 and Its 0.875% Senior Unsecured Convertible Notes due 2021". Venlo....
-  Qiagen N.V.. (1/18/17). "Press Release: Qiagen Announces Details for Completion of approximately $250 Million Synthetic Share Repurchase". Venlo....
-  Qiagen N.V.. (1/9/17). "Press Release: Qiagen Enhances Bioinformatics Portfolio with Acquisition of OmicSoft". Hilden & Germantown, MD....
-  HTG Molecular Diagnostics, Inc.. (11/16/16). "Press Release: HTG Molecular Diagnostics and Qiagen Team Up to Advance Precision Diagnostics". Tucson, AZ & Venlo....
-  Qiagen N.V.. (11/9/16). "Press Release: Qiagen’s GeneReader NGS System Streamlines Data Management for Labs". Hilden & Charlotte, NC....
-  Qiagen N.V.. (11/9/16). "Press Release: Qiagen GeneReader NGS System to Relaunch in U.S. Market". Charlotte, NC & Hilden....
-  Qiagen N.V.. (11/2/16). "Press Release: Qiagen Launches Restructuring Initiatives, Revises Outlook for 2016 Earnings and Provides Initial Net Sales and Adjusted Earnings Guidance for 2017". Venlo....
-  Qiagen N.V.. (11/2/16). "Press Release: Qiagen Reports Results for Third Quarter and First Nine Months of 2016". Venlo....
To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to email@example.com and simply fill the subject line with the word »LSG newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)